BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters

Recent developments in oncology treatments show contrasting results for mRNA technology. BioNTech has decided to terminate its mid-stage trial for an mRNA cancer vaccine. Conversely, a late-stage trial involving a cancer vaccine developed by Moderna and Merck has achieved success. These updates highlight the volatile nature of clinical trials in the biotechnology sector as companies like Moderna and Merck advance while BioNTech halts specific research paths in its quest to treat cancer patients.